Re: Dugel et al: HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration (Ophthalmology. 2019 Apr 12 [Epub ahead of print]) Reply

Author(s):: Dugel, P.U.; Koh, A.; Ogura, Y.; Jaffe, G.J.; Schmidt-Erfurth, U.; Brown, D.M.; Gomes, A.V.; Warburton, J.; Weichselberger, A.; Holz, F.G.; HAWK Study Investigator; HARRIER Study Investigator

Published: 2019
Publication type: Article / Letter to editor

Date issued: 2019-12-01
Language: English
Publisher: ELSEVIER SCIENCE INC
Is part of
hdl: 1887/122654
doi: 10.1016/j.ophtha.2019.08.016